Nurix Therapeutics Inc - Asset Resilience Ratio
Nurix Therapeutics Inc (NRIX) has an Asset Resilience Ratio of 67.06% as of August 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Explore NRIX long-term investments to assets to see how much of total assets are deployed in long-term investments.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Nurix Therapeutics Inc's Asset Resilience Ratio has changed over time. See defensive interval ratio of Nurix Therapeutics Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets Composition Over Time
This chart breaks down Nurix Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see NRIX asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $350.39 Million | 67.06% |
| Total Liquid Assets | $350.39 Million | 67.06% |
Asset Resilience Insights
- Very High Liquidity: Nurix Therapeutics Inc maintains exceptional liquid asset reserves at 67.06% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Nurix Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Nurix Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
BRITANNIA LIFE SCIENCES
F:L020 |
Biotechnology | 63.76% |
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
ABCELLERA BIOLOGICS
F:8QQ |
Biotechnology | 29.87% |
Annual Asset Resilience Ratio for Nurix Therapeutics Inc (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Nurix Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-11-30 | 74.64% | $499.59 Million | $669.34 Million | +9.04pp |
| 2023-11-30 | 65.60% | $233.28 Million | $355.60 Million | +6.90pp |
| 2022-11-30 | 58.71% | $244.67 Million | $416.76 Million | +13.57pp |
| 2021-11-30 | 45.14% | $215.21 Million | $476.77 Million | +4.32pp |
| 2020-11-30 | 40.82% | $161.79 Million | $396.34 Million | +34.23pp |
| 2019-11-30 | 6.59% | $2.90 Million | $44.05 Million | -23.03pp |
| 2018-11-30 | 29.62% | $13.45 Million | $45.40 Million | -- |
About Nurix Therapeutics Inc
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-ce… Read more